You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物-B(06998.HK)全年研發開支增加至6.966億元
格隆匯 03-23 18:31

格隆匯 3 月 23日丨嘉和生物-B(06998.HK)發佈截至2020年12月31日止年度全年業績公吿,報吿期內,總收益為人民幣1030萬元,主要來自根據按服務收費合約向客户提供研究及製造服務。期內研發開支為人民幣6.966億元,而2019年年度則為人民幣4.388億元。有關支出主要歸因於集團正在進行的臨牀試驗開支增加及員工薪金及相關福利成本。

報吿期內,全面虧損總額為人民幣30.328億元,而2019年年度則為人民幣5.23億元,主要由於根據香港財務報吿準則,優先股於公司首次公開發售中轉換為普通股後,集團就優先股公允價值虧損淨額錄得非經常性虧損人民幣19.338億元。根據非香港財務報吿準則計量,報吿期內,經調整虧損為人民幣6.546億元。

公司為一家正在進入商業化階段的生物製藥公司,專注於腫瘤及自身免疫藥物的研發及商業化。公司於2020年10月7日成功於聯交所上市並開始買賣。2020年,公司管線中候選藥物的開發及業務營運取得顯著進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account